REPLAY Study Group. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study.J Child Neurol. 2013 Jul;28(7):849-56. doi: 10.1177/0883073813488828. Epub 2013 May 10

Autor: Tenembaum, Sn, Banwell, B, Pohl, D, Krupp, Lb, Boyko, A, Meinel, M, Lehr, L, Rocak, S, Cantogno, Ev, Moraga, Ms, Ghezzi, A, Capobianco, M, Gonzaga, S, Chitnis, T, Deiva, K, Gouider Khouja, N, Marrosu, Mg, Martinelli, V, Ness, J, Patterson, Mc, Patti, F, Emanuele, Pv, Pena, J, Pozzilli, Carlo, Waubant, E, Guttman Weinstock, B, Baroncini, D.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3686::addab795eede8f8155329100d3164d13
http://hdl.handle.net/11573/762937

Global Safety Assessment of Adverse Events of Special Interest Following 2 Years of Use and 772 Million Administered Doses of mRNA-1273.

Autor: Urdaneta V; Clinical Safety and Risk Management, Moderna, Inc, Cambridge, Massachusetts, USA., Esposito DB; Medical Affairs, Moderna, Inc, Cambridge, Massachusetts, USA., Dharia P; Medical Affairs, Moderna, Inc, Cambridge, Massachusetts, USA., Moraga MS; Clinical Safety and Risk Management, Moderna, Inc, Cambridge, Massachusetts, USA., Anteyi K; Clinical Safety and Risk Management, Moderna, Inc, Cambridge, Massachusetts, USA., Oduyebo-Omotosho T; Clinical Safety and Risk Management, Moderna, Inc, Cambridge, Massachusetts, USA., Rossi M; Clinical Safety and Risk Management, Moderna, Inc, Cambridge, Massachusetts, USA., Burton P; Medical Affairs, Moderna, Inc, Cambridge, Massachusetts, USA.; Clinical Safety and Pharmacovigilance, Moderna, Inc, Cambridge, Massachusetts, USA., Vega JM; Clinical Safety and Pharmacovigilance, Moderna, Inc, Cambridge, Massachusetts, USA., Dawson R; Medical Affairs, Moderna, Inc, Cambridge, Massachusetts, USA., Straus W; Clinical Safety and Pharmacovigilance, Moderna, Inc, Cambridge, Massachusetts, USA.

Publikováno v: Open forum infectious diseases [Open Forum Infect Dis] 2024 Feb 02; Vol. 11 (3), pp. ofae067. Date of Electronic Publication: 2024 Feb 02 (Print Publication: 2024).

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

Autor: Comi G; Department of Neurology, Ospedale San Raffaele, Milan, Italy. g.comi@hsr.it, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L

Publikováno v: The Lancet. Neurology [Lancet Neurol] 2012 Jan; Vol. 11 (1), pp. 33-41. Date of Electronic Publication: 2011 Dec 04.

Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy.

Autor: Sandberg-Wollheim M; Department of Neurology, University Hospital, Lund, Sweden. magnhild.sandberg_wollheim@med.lu.se, Alteri E, Moraga MS, Kornmann G

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2011 Apr; Vol. 17 (4), pp. 423-30. Date of Electronic Publication: 2011 Jan 10.